Royalty Pharma (RPRX) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Royalty Pharma (RPRX) do?
Royalty Pharma plc (RPRX) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Funds biopharmaceutical development in exchange for future cash streams from approved therapies. Collects royalties on commercial medicines marketed by third-party pharmaceutical partners. Buys biopharmaceutical royalties directly from research institutions and inventors without running laboratory trials or. It is worth $38.85B on the market and sold $2.62B over the last year.
- Market cap
- $38.85B
- P/E ratio
- 44.1×
- Annual sales
- $2.62B
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 14, 2026
RPRX’s flags, in plain English
Each flag is a number from Royalty Pharma’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 14, 2026.
Wide Gross Margin
Gross margin of 99.8% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Fat Margins
Profit margin of 25.7%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.
Cheap on Cash Flow
Priced at 13 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.
Debt Is Driving
Heavy debt, 126% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.
2 more green flags and 2 more risk notes open with the free trial. Try it free for 7 days.
Questions about RPRX
How big is Royalty Pharma?
Royalty Pharma’s market cap is $38.85B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $2.62B: what customers paid the company over the last year, before any costs.
What is RPRX’s P/E ratio?
RPRX’s P/E ratio is 44.1×. Investors pay about 44.1 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with RPRX?
A large percentage of total royalty receipts relies on a small group of cystic fibrosis drugs marketed by Vertex. That is one risk on Royalty Pharma’s card. Its first risk flag is Debt Is Driving, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Royalty Pharma’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. RPRX’s filings on SEC.gov. The Margin Monkey is research, not advice.
